Replicate Bioscience has early evidence its self-replicating RNA technology works in humans. The Apple Tree Partners biotech showed all doses of its rabies vaccine triggered protective responses, ...
Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate's novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP ...
Novo Nordisk has both internal research and external alliances pursuing new drugs that could shape the next generation of metabolic medicines. The pharmaceutical giant’s latest move is a partnership ...
This is the second of two articles on a temperature-sensitive self-replicating RNA vaccine; click here for part one. They form part of a broader series on next-generation mRNA vaccines. The first ...
As the world continues to combat various infectious diseases, the development of novel vaccine technologies remains at the forefront of scientific research. mRNA-based vaccines and utilization of ...
Immorna Biotechnology Co. Ltd. raised nearly $100 million in series A+ and A++ financing rounds to speed up the clinical development and commercialization of its RNA-based therapeutics. Founded in ...
Hosted on MSN
Human cells self-destruct when viruses mess with RNA
A groundbreaking study reveals that human cells initiate self-destruction processes when viruses disrupt RNA production, offering new insights into innate antiviral defenses. Conducted and reported on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results